JUL 22, 2021 5:00 PM EDT

Closing Keynote Presentation Response to Second Generation CAR T Cell Therapy: It takes (at least) Two to Tango

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor, Pathology and Laboratory Medicine, University of Pennsylvania and Director, Biomarker Program, Parker Institute for Cancer Immunotherapy, UPenn
    BIOGRAPHY

Abstract

Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this therapy has hit a glass ceiling w.r.t. initial and durable remissions. Inclusion of a costimulatory domain in the CAR design have solved much of limited clinical efficacy issues, some challenges remained. We have recently demonstrated that T cell-intrinsic mechanisms solved part of the glass ceiling conundrum in leukemia, we recently demonstrated that primary chronic lymphocytic leukemia cells elicit a blunted response of second generation CAR T cells, even when using normal donor CAR-engineered T cells. In my talk I will highlight our discoveries in T cell- and tumor-intrinsic determinants of anti-CD19 CAR T cell responses in this disease.

Learning Objectives:

1. Classify the Chimeric Antigen Receptor (CAR)-engineered T cells have dramatically altered the clinical outlook for many blood cancers

2. Identify that with the discovery of costimulation as a critical component of an effective T cell responses and the inclusion of such domains in CAR design we have overcome previous significant roadblocks, but encountered new challenges along the way

3. Recognize the part of what explains response and resistance to this therapy is T cell-intrinsic; however, even the most efficacious CAR showed ineffective against primary tumor cells

4. Summarize the highlights of some of our discoveries in elucidating T cell- and tumor-cell-intrinsic determinants of CAR T cell efficacy


Show Resources
You May Also Like
MAY 19, 2022 8:00 AM PDT
MAY 19, 2022 8:00 AM PDT
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAR 29, 2022 9:00 AM PDT
C.E. CREDITS
MAR 29, 2022 9:00 AM PDT
Date: March 29, 2022 Time: 09:00am (PDT), 12:00pm (EDT), 17:00 (GMT) Advances in molecular and immunodiagnostics are enabling a personalized, high-precision approach to health in many clin...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
FEB 24, 2022 9:00 AM PST
C.E. CREDITS
FEB 24, 2022 9:00 AM PST
Date: February 24, 2021 Time: 9:00am (PST), 12:00pm (EST) Cytokine profiling is a valuable tool used in preclinical research for monitoring an immune response and cell signaling pathways dur...
DEC 07, 2021 10:00 AM PST
C.E. CREDITS
DEC 07, 2021 10:00 AM PST
Date: December 07, 2021 Time: 10:00am (PST) The RNAscope™ technology allows high sensitivity and spatial resolution providing pivotal single-cell information to gain better insights in...
Loading Comments...
Show Resources